The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 401–500 of 1,001
Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kinetics
Daryaee, F., & Tonge, P. J. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.03.008 · Cited by 64
Voice, A. T., Tresadern, G., Twidale, R. M., van Vlijmen, H., & Mulholland, A. J. (2021) · Chemical Science · doi:10.1039/d0sc06122k · Cited by 58
Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development
Nam, K., Shao, Y., Major, D. T., & Wolf‐Watz, M. (2024) · ACS Omega · doi:10.1021/acsomega.3c09084 · Cited by 85
Multi-tiered chemical proteomic maps of tryptoline acrylamide–protein interactions in cancer cells
Njomen, E., Hayward, R. E., DeMeester, K. E., Ogasawara, D., Dix, M. M., Nguyen, T., Ashby, P., Simon, G. M., Schreiber, S. L., Melillo, B., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01601-1 · Cited by 53
“…,3 R ) stere-oisomer also stereoselectively engaged a greater number of proteins isotype-restricted nucleophilic amino acids within sets of related proteins; and (3) sustained pharmacological activity that is dependent on protein turnover rather than the pharmacokinetics of small molecules 14,15 .”
De Cesco, S., Deslandes, S., Therrien, E., Levan, D., Cueto, M., Schmidt, R., Cantin, L.-D., Mittermaier, A., Juillerat-Jeanneret, L., & Moitessier, N. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002839 · Cited by 55
Discovery of Potent and Specific Dihydroisoxazole Inhibitors of Human Transglutaminase 2
Klöck, C., Herrera, Z., Albertelli, M. A., & Khosla, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501145a · Cited by 55
Chan, A. H., Lee, W., Spasov, K. A., Cisneros, J. A., Kudalkar, S. N., Petrova, Z. O., Buckingham, A. B., Anderson, K. S., & Jorgensen, W. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711463114 · Cited by 56
An Easy, General and Practical Method for the Construction of Alkyl Sulfonyl Fluorides
Zhang, X., Fang, W., Lekkala, R., Tang, W., & Qin, H. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000515 · Cited by 55
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Lategahn, J., Keul, M., Klövekorn, P., Tumbrink, H. L., Niggenaber, J., Müller, M. P., Hodson, L. E., Flaßhoff, M., Hardick, J., Grabe, T., et al. (2019) · Chemical Science · doi:10.1039/c9sc03445e · Cited by 63
Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization
Crowley, V. M., Thielert, M., & Cravatt, B. F. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01336 · Cited by 54
Targeting Protein Kinases Degradation by PROTACs
Yu, F., Cai, M., Shao, L., & Zhang, J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.679120 · Cited by 52
“Several selective small-molecular anticancer drugs have been developed in the past few decades (Singh et al., 2011; Ward et al., 2020).”
BackgroundBrogi, S., Ibba, R., Rossi, S., Butini, S., Calderone, V., Gemma, S., & Campiani, G. (2022) · Molecules · doi:10.3390/molecules27082561 · Cited by 54
“non-covalent drugs and many of the challenges linked to such a mechanism in the field of drug design [59].”
BackgroundOyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Adeyemi, A. O., Temionu, O. R., Adelusi, T. I., Abdul-Hammed, M., Elegbeleye, O. E., & Odunitan, T. T. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10523-4 · Cited by 59
“However, these effects are frequently caused by highly reactive metabolites, and with a better knowledge of the reactivity requirements for covalent inhibitors, interest in the topic has resurged [1].”
BackgroundYang, P., Wang, M., Li, L., Wu, H., He, C. Y., & Yao, S. Q. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201103322 · Cited by 54
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3
Muth, F., El‐Gokha, A., Ansideri, F., Eitel, M., Döring, E., Sievers‐Engler, A., Lange, A., Boeckler, F. M., Lämmerhofer, M., Koch, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01180 · Cited by 55
Sana, S., Tokala, R., Bajaj, D. M., Nagesh, N., Bokara, K. K., Kiranmai, G., Lakshmi, U. J., Vadlamani, S., Talla, V., & Shankaraiah, N. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103317 · Cited by 52
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Baillie, T. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1832079 · Cited by 57
Self-citationCovPDB: a high-resolution coverage of the covalent protein–ligand interactome
Gao, M., Moumbock, A. F. A., Qaseem, A., Xu, Q., & Günther, S. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab868 · Cited by 56
Chemoproteomics‐Enabled Discovery of a Potent and Selective Inhibitor of the DNA Repair Protein MGMT
Wang, C., Abegg, D., Hoch, D. G., & Adibekian, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511301 · Cited by 51
Bruno, S., Pinto, A., Paredi, G., Tamborini, L., Micheli, C. D., Pietra, V. L., Marinelli, L., Novellino, E., Conti, P., & Mozzarelli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500747h · Cited by 53
Taldone, T., Kang, Y., Patel, H. J., Patel, M. R., Patel, P. D., Rodina, A., Patel, Y., Gozman, A., Maharaj, R., Clement, C. C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401552y · Cited by 53
Ai, Y.-B., Yu, L.-L., Tan, X., Chai, X., & Liu, S. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00334 · Cited by 56
A comparative study of warheads for design of cysteine protease inhibitors
da Silva, D. G., Ribeiro, J. F. R., Vita, D. D., Cianni, L., Franco, C. H., Freitas-Junior, L. H., Moraes, C. B., da Rocha, J. R., Burtoloso, A. C. B., Kenny, P. W., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.002 · Cited by 53
Update on drug development targeting parasite cysteine proteases
McKerrow, J. H. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0005850 · Cited by 53
Designed covalent allosteric modulators: an emerging paradigm in drug discovery
Lu, S., & Zhang, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.013 · Cited by 55
Marine Invertebrate Natural Products that Target Microtubules
Miller, J. H., Field, J. J., Kanakkanthara, A., Owen, J. G., Singh, A. J., & Northcote, P. T. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00964 · Cited by 54
do Amaral, D. N., Lategahn, J., Fokoue, H. H., da Silva, E. M. B., Sant’Anna, C. M. R., Rauh, D., Barreiro, E. J., Laufer, S., & Lima, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-018-36846-7 · Cited by 53
Zhou, H., Lü, J., Chinnaswamy, K., Stuckey, J. A., Liu, L., McEachern, D., Yang, C., Bernard, D., Shen, H., Rui, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22924-4 · Cited by 53
Macip, G., Garcia‐Segura, P., Mestres‐Truyol, J., Saldivar‐Espinoza, B., Pujadas, G., & García-Vallvé, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010259 · Cited by 58
“However, conventional IC50 measurements are of limited value for characterizing the potency of irreversible covalent inhibitors, because incubation for different periods of time would provide different IC50 values [42].”
BackgroundBiospecific Chemistry for Covalent Linking of Biomacromolecules
Cao, L., & Wang, L. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00066 · Cited by 54
“117,118 Traditionally, drug development has focused on small molecules due to their diverse chemical makeup and ability to precisely target specific areas within proteins.”
BackgroundWu, S., Luo, H., Wang, H., Zhao, W., Hu, Q., & Yang, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.109 · Cited by 51
Leung, L. Y., Yang, X., Strelevitz, T. J., Montgomery, J. I., Brown, M. F., Zientek, M. A., Banfield, C. R., Gilbert, A. M., Thorarensen, A., & Dowty, M. E. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.072983 · Cited by 52
EnzyDock: Protein–Ligand Docking of Multiple Reactive States along a Reaction Coordinate in Enzymes
Das, S., Shimshi, M., Raz, K., Nitoker, N., Mhashal, A. R., Ansbacher, T., & Major, D. T. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00366 · Cited by 57
Covalent PROTACs: the best of both worlds?
Grimster, N. P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00191d · Cited by 46
Tunable Cysteine-Targeting Electrophilic Heteroaromatic Warheads Induce Ferroptosis
Karaj, E., Sindi, S. H., Kuganesan, N., Perera, L., Taylor, W. R., & Tillekeratne, L. M. V. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00909 · Cited by 57
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41
Yi, H. A., Fochtman, B. C., Rizzo, R. C., & Jacobs, A. (2016) · Current HIV Research · doi:10.2174/1570162x14999160224103908 · Cited by 56
Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking
Zhang, H., Jiang, W., Chatterjee, P., & Luo, Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00959 · Cited by 57
“ΔΔGdm = ΔGdm L − ΔGdm ref = ΔGnoncov − ΔGsolv (4)”
Li, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
“, aspirin and penicillin), and covalent drugs have become a focus in anticancer and antiviral drug discovery (Kalgutkar and Dalvie, 2012; Singh et al., 2011).”
Basu, D., Richters, A., & Rauh, D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.038 · Cited by 50
Yuce, M., Çiçek, E., İnan, T., Dağ, A. B., Kürkçüoğlu, Ö., & Sungur, F. A. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26164 · Cited by 49
Viral infections and drug hypersensitivity
Pichler, W. J., & Brüggen, M. (2022) · Allergy · doi:10.1111/all.15558 · Cited by 66
“P-i stimulations may happen with all drugs, including drugs that have hapten-like characteristics, as covalent bonds are always preceded by non-covalent drug binding to a suitable site in the protein [10, 34].”
BackgroundScicinski, J. J., Oronsky, B. T., Taylor, M., Luo, G., Musick, T. J., Marini, J., Adams, C. M., & Fitch, W. L. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.046755 · Cited by 50
Miyahisa, I., Sameshima, T., & Hixon, M. S. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505800 · Cited by 49
Bae, H., Jang, J. Y., Choi, S., Lee, J., Kim, H., Jo, A., Lee, K., Choi, J. H., Suh, S. W., & Park, S. B. (2016) · Chemical Science · doi:10.1039/c6sc01279e · Cited by 47
Guardiola, S., Prades, R., Mendieta, L., Brouwer, A. J., Streefkerk, J., Nevola, L., Tarragó, T., Liskamp, R. M. J., & Giralt, E. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.04.013 · Cited by 53
“From a kinetic perspective, covalent drugs block their targets in a two-step fashion (Singh et al., 2011).”
BackgroundGlutamine transporters as pharmacological targets: From function to drug design
Scalise, M., Pochini, L., Galluccio, M., Console, L., & Indiveri, C. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.02.005 · Cited by 57
Insect Acetylcholinesterase as a Target for Effective and Environmentally Safe Insecticides
Pang, Y. (2014) · Advances in insect physiology · doi:10.1016/b978-0-12-417010-0.00006-9 · Cited by 55
Cov_DOX: A Method for Structure Prediction of Covalent Protein–Ligand Bindings
Wei, L., Chen, Y., Liu, J., Rao, L., Ren, Y., Xu, X., & Wan, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02007 · Cited by 50
Peptide‐based covalent inhibitors of protein–protein interactions
Paulussen, F. M., & Grossmann, T. N. (2022) · Journal of Peptide Science · doi:10.1002/psc.3457 · Cited by 58
“orated with a protein-reactive functional group (modifier), so-called targeted covalent inhibitors, attracted attention.(32,33) Notably, such”
BackgroundReactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
“Despite these advantages, TCIs can show high toxicity due to off-target interactions [1,8,19].”
BackgroundSulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry
Reddi, R. N., Rogel, A., Gabizon, R., Rawale, D. G., Harish, B., Marom, S., Tivon, B., Arbel, Y. S., Gurwicz, N., Oren, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08853 · Cited by 53
Mechanism-based inactivator of isocitrate lyases 1 and 2 from Mycobacterium tuberculosis
Pham, T. V., Murkin, A. S., Moynihan, M. M., Harris, L., Tyler, P. C., Shetty, N., Sacchettini, J. C., Huang, H.-L., & Meek, T. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706134114 · Cited by 49
Ishii, T., Okai, T., Iwatani-Yoshihara, M., Mochizuki, M., Unno, S., Kuno, M., Yoshikawa, M., Shibata, S., Nakakariya, M., Yogo, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12513-1 · Cited by 48
Ge, W., Hao, X., Han, F., Liu, Z., Wang, T., Wang, M., Chen, N., Ding, Y., Chen, Y., & Zhang, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.058 · Cited by 49
Thiyagarajan, T., Ponnusamy, S., Hwang, D., He, Y., Asemota, S., Young, K. L., Johnson, D. L., Bocharova, V., Zhou, W., Jain, A. K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211832120 · Cited by 52
“For a covalent molecule to be effective and selective, it first has to bind noncovalently to a binding region and then form a covalent bond with an appropriate nucleophile (65).”
BackgroundMeur, A. M., Ghisdal, P., Mullier, B., Ron, P. D., Downey, P. M., Perren, C. V. D., Declercq, V., Cornelis, S., Famelart, M., van Asperen, J., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12343 · Cited by 53
Suh, E. H., Liu, Y., Connelly, S., Genereux, J. C., Wilson, I. A., & Kelly, J. W. (2013) · Journal of the American Chemical Society · doi:10.1021/ja408230k · Cited by 48
Alkoxyamines: Toward a New Family of Theranostic Agents against Cancer
Moncelet, D., Voisin, P. J., Koonjoo, N., Bouchaud, V., Massot, P., Parzy, E., Audran, G., Franconi, J., Thiaudière, E., Marque, S. R. A., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001394 · Cited by 48
Vicente‐Blázquez, A., González, M., Álvarez, R., Mazo, S. D., Medarde, M., & Peláez, R. (2018) · Medicinal Research Reviews · doi:10.1002/med.21541 · Cited by 52
Yang, X., van Veldhoven, J. P. D., Offringa, J., Kuiper, B. J., Lenselink, E. B., Heitman, L. H., van der Es, D., & IJzerman, A. P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02026 · Cited by 54
Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A., Bonelli, M. A., Monica, S. L., Cretella, D., Alfieri, R. R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00179 · Cited by 48
Kinetic Template‐Guided Tethering of Fragments
Nonoo, R. H., Armstrong, A., & Mann, D. J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200404 · Cited by 47
Fanfrlík, J., Brahmkshatriya, P. S., Řezáč, J., Jílková, A., Horn, M., Mareš, M., Hobza, P., & Lepšík, M. (2013) · The Journal of Physical Chemistry B · doi:10.1021/jp409604n · Cited by 47
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Huisman, M., White, J. K., Lewalski, V. G., Podgorski, I., Turró, C., & Kodanko, J. J. (2016) · Chemical Communications · doi:10.1039/c6cc07083c · Cited by 47
Allimuthu, D., & Adams, D. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00424 · Cited by 49
Olp, M. D., Sprague, D. J., Goetz, C. J., Kathman, S. G., Wynia‐Smith, S. L., Shishodia, S., Summers, S. B., Xu, Z., Statsyuk, A. V., & Smith, B. C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00058 · Cited by 47
Jung, S., Fuchs, N. S., Johé, P., Wagner, A., Diehl, E., Yuliani, T., Zimmer, C., Barthels, F., Zimmermann, R. A., Klein, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01002 · Cited by 46
BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer
Cenni, B., Gutmann, S., & Gottar, M. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.663838 · Cited by 49
Hahne, G., & Grossmann, T. N. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.050 · Cited by 46
Martínez‐Useros, J., & García‐Foncillas, J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.02.092 · Cited by 48
New drug design with covalent modifiers
Adeniyi, A. A., Ramesh, M., & Soliman, M. E. S. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1115478 · Cited by 48
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
Hossam, M., Lasheen, D. S., & Abouzid, K. A. M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600063 · Cited by 49
BIreactive: A Machine-Learning Model to Estimate Covalent Warhead Reactivity
Palazzesi, F., Hermann, M. R., Grundl, M. A., Pautsch, A., Seeliger, D., Tautermann, C. S., & Weber, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01058 · Cited by 49
Design, Synthesis, and Structural Characterization of Lysine Covalent BH3 Peptides Targeting Mcl-1
Gambini, L., Udompholkul, P., Baggio, C., Muralidharan, A., Kenjić, N., Assar, Z., Perry, J. J. P., & Pellecchia, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00005 · Cited by 48
Liu, X., Xu-Liu, Pang, X., Yuan, X. Y., Yu, G.-X., Li, Y.-R., Guan, Y.-F., Zhang, Y., Song, J., Zhang, Q., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116358 · Cited by 50
Qin, H., Zheng, Q., Bare, G. A. L., Wu, P., & Sharpless, K. B. (2016) · Angewandte Chemie · doi:10.1002/ange.201608807 · Cited by 46
Recent Advances on Targeting Proteases for Antiviral Development
Borges, P. H. O., Ferreira, S. B., & Silva, F. P. (2024) · Viruses · doi:10.3390/v16030366 · Cited by 51
“…stages: (i) interaction of the inhibitor with the target protease via non-covalent bonds, which depends on the overall structure of the ligand and the active site, and (ii) reaction of the ligand with the catalytic residue via covalent bond formation [76], which will depend on the warhead group.”
BackgroundProfiling the proteome-wide selectivity of diverse electrophiles
Zanon, P. R. A., Yu, F., Musacchio, P. Z., Lewald, L., Zollo, M., Krauskopf, K., Mrdović, D., Raunft, P., Maher, T. E., Cigler, M., et al. (2025) · Nature Chemistry · doi:10.1038/s41557-025-01902-z · Cited by 117
“Covalent inhibitors are powerful entities in drug discovery with key advantages including increased binding affinity to the target, the potential to generate selectivity among closely related proteins and improved pharmacodynamic properties 1 .”
Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 55
CNS Anticancer Drug Discovery and Development Conference White Paper
Levin, V. A., Tonge, P. J., Gallo, J. M., Birtwistle, M. R., Dar, A. C., Iavarone, A., Paddison, P. J., Heffron, T. P., Elmquist, W. F., Lachowicz, J. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov169 · Cited by 47
Self-citationNonpeptidic Selective Inhibitors of the Chymotrypsin‐Like (β5 i) Subunit of the Immunoproteasome
Sosič, I., Gobec, M., Brus, B., Knez, D., Živec, M., Konc, J., Lešnik, S., Ogrizek, M., Obreza, A., Žigon, D., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201600190 · Cited by 47
Inhibition of Beta-Amyloid Fibrillation by Luminescent Iridium(III) Complex Probes
Lu, L., Zhong, H., Wang, M., Ho, S., Li, H., Leung, C., & Ma, D. (2015) · Scientific Reports · doi:10.1038/srep14619 · Cited by 51
Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors
Zaro, B. W., Whitby, L. R., Lum, K. M., & Cravatt, B. F. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10589 · Cited by 45
Wu, J., Kumar, S., Wang, F., Wang, H., Chen, L., Arsenault, P., Mattern, M. R., & Weinstock, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00498 · Cited by 49
Explicit Treatment of Non‐Michaelis‐Menten and Atypical Kinetics in Early Drug Discovery**
Srinivasan, B. (2020) · ChemMedChem · doi:10.1002/cmdc.202000791 · Cited by 48
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 46
“Furthermore, covalent drugs demonstrated a reduced risk for resistance mutations as irreversibility is irrelevant to the extent of inhibition (Tables 1 and 2, Figure 17).(374,376) Moreover, it is even possible that covalent approaches could conquer the traditional challenges with IDPs.”
BackgroundHomobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Yan, J., Li, T., Miao, Z., Wang, P., Sheng, C., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00728 · Cited by 47
Qin, Z., Zhang, K., He, P., Zhang, X., Xie, M., Fu, Y., Gu, C., Zhu, Y., Tong, A., Wei, H., et al. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01304-z · Cited by 48
“The list of all of the NGS reads of each SuFEx in vitro selection are provided in Supplementary Data 3.”
BackgroundInfluentialCHARMM-GUI PDB Reader and Manipulator: Covalent Ligand Modeling and Simulation
Kong, L., Park, S., & Im, W. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168554 · Cited by 48
Ding, Y., Li, D., Ding, C., Wang, P., Liu, Z., Wold, E. A., Ye, N., Chen, H., White, M. A., Shen, Q., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01514 · Cited by 45
Piesche, M., Roos, J., Kuhn, B. R., Fettel, J., Hellmuth, N., Brat, C., Maucher, I. V., Awad, O., Matrone, C., Comerma-Steffensen, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01297 · Cited by 47
Li, K. S., Quinn, J. G., Saabye, M. J., Guerrero, J. F. S., Nonomiya, J., Lian, Q., Phung, W., Izrayelit, Y., Walters, B. T., Gustafson, A. E., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04463 · Cited by 48
Reaction-based fluorogenic probes for detecting protein cysteine oxidation in living cells
Ferreira, R. B., Fu, L., Jung, Y., Yang, J. H., & Carroll, K. S. (2022) · Nature Communications · doi:10.1038/s41467-022-33124-z · Cited by 47
Baldwin, E. T., Götte, M., Tchesnokov, E. P., Arnold, E., Hagel, M., Nichols, C. E., Dossang, P., Lamers, M. B. A. C., Wan, P., Steinbacher, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200260119 · Cited by 47
Nucleophilic covalent ligand discovery for the cysteine redoxome
Fu, L., Jung, Y., Tian, C., Ferreira, R. B., Cheng, R., He, F., Yang, J. H., & Carroll, K. S. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01330-5 · Cited by 49
“Targeted covalent inhibitors 1 and degraders 2 have emerged as a promising therapeutic class.”
Background1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases
Tan, X., Furio, L., Reboud‐Ravaux, M., Villoutreix, B. O., Hovnanian, A., & Amri, C. E. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.039 · Cited by 43
Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors
Vogt, D., Weber, J., Ihlefeld, K., Brüggerhoff, A., Proschak, E., & Stark, H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.044 · Cited by 46
Shi, C., Geders, T. W., Park, S. W., Wilson, D. J., Boshoff, H. I., Abayomi, O., Barry, C. E., Schnappinger, D., Finzel, B. C., & Aldrich, C. C. (2011) · Journal of the American Chemical Society · doi:10.1021/ja204036t · Cited by 43
Palermo, G., Branduardi, D., Masetti, M., Lodola, A., Mor, M., Piomelli, D., Cavalli, A., & Vivo, M. D. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2004283 · Cited by 44
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.